Evaluation of the Pathobiology of CALR-mutated MPN Cells

Part of paid clinical trials in Charlotte, North Carolina.

Sponsor
Wake Forest University Health Sciences
Study ID
NCT06480591
Status
Recruiting
Apply to this trial

Conditions

  • Myeloproliferative Neoplasm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Blood Draw — OTHER
    The amount of blood that will be collected for this is 50 mL(milliliters), or about 3 ½ tablespoons.

Study Details

The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.

Key Dates

Start date
Jan 21, 2025
Status verified
May 2026
Primary completion
Jul 31, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
35 participants (estimated)

Arms

  • Arm: JAK2 V617F mutation positive MPN patients
    Patients with MPN disease with a JAK2 mutation
  • Arm: CALR-mutation positive patients
    Patients with MPN disease with a CALR mutation

Primary Outcome Measure

Expression levels of TLR 2 and TLR 4 [ Time Frame: 24 months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Atrium Health Levine CancerCharlotteNorth Carolina28204
Courtney Schepel
[email protected]
(980) 292-0817
Aleksander Chojecki, MD (PRINCIPAL_INVESTIGATOR)
Wake Forest Baptist Comprehensive Cancer CenterWinston-SalemNorth Carolina27157
Ruben Mesa, MD
[email protected]
336-716-4618
Ruben Mesa, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Charlotte, NC

By research site
Atrium Health Levine Cancer· Charlotte, NCWake Forest Baptist Comprehensive Cancer Center· Winston-Salem, NC

Related Studies